Mbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage

Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes. Palmitic acid (PA)-treated β-cells, db/db mice and high fat diet (HFD)-fed mouse model of type 2 diabetes were established. H&E was used t...

Full description

Saved in:
Bibliographic Details
Published inMolecular medicine (Cambridge, Mass.) Vol. 30; no. 1; pp. 229 - 19
Main Authors Gong, Yingying, Wei, Meilin, Cao, Xiaopei, Xu, Changliu, Jin, Jiewen, Pei, Ling, Li, Yanbing, Xiao, Haipeng, Wu, Liting
Format Journal Article
LanguageEnglish
Published England BioMed Central 23.11.2024
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes. Palmitic acid (PA)-treated β-cells, db/db mice and high fat diet (HFD)-fed mouse model of type 2 diabetes were established. H&E was used to assess the histological changes of pancreas. IHC, FISH, western blot or qRT-PCR was employed to detect the expression of key molecules in primary islets or lipotoxic β-cells. Cell behaviors were detected by MTT, EdU incorporation assay, TUNEL assay and glucose-induced insulin secretion (GSIS). The associations among circMlxipl, Mbnl1 and Rbbp6 were validated by RIP and RNA pull-down assays, and the direct binding between Hdac3 and Mbnl1 promoter was examined by ChIP and luciferase assays. Co-IP was employed to assess the interaction between ChREBP and Rbbp6, as well as the ubiquitination of ChREBP. Hdac3 and ChREBP were upregulated, but Mbnl1 and circMlxipl were downregulated in islets from diabetic mice and lipotoxic β-cells. Mbnl1 overexpression protected against PA-induced impairments in lipotoxic β-cells through modulating back-splicing of circMlxipl and suppressing ChREBP. Hdac3 served as a transcriptional repressor of Mbnl1, and it was implicated in circMlxipl-mediated protection via regulating ChREBP expression in lipotoxic β-cells. Lack of circMlxipl inhibited Rbbp6-mediated ubiquitin-proteasomal degradation of ChREBP in lipotoxic β-cells. In vivo studies revealed that Hdac3 knockdown or Mbnl1 overexpression alleviated diabetes symptoms through circMlxipl-regulated ChREBP in diabetic mice. Mbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage.
AbstractList Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes.BACKGROUNDDiabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes.Palmitic acid (PA)-treated β-cells, db/db mice and high fat diet (HFD)-fed mouse model of type 2 diabetes were established. H&E was used to assess the histological changes of pancreas. IHC, FISH, western blot or qRT-PCR was employed to detect the expression of key molecules in primary islets or lipotoxic β-cells. Cell behaviors were detected by MTT, EdU incorporation assay, TUNEL assay and glucose-induced insulin secretion (GSIS). The associations among circMlxipl, Mbnl1 and Rbbp6 were validated by RIP and RNA pull-down assays, and the direct binding between Hdac3 and Mbnl1 promoter was examined by ChIP and luciferase assays. Co-IP was employed to assess the interaction between ChREBP and Rbbp6, as well as the ubiquitination of ChREBP.METHODSPalmitic acid (PA)-treated β-cells, db/db mice and high fat diet (HFD)-fed mouse model of type 2 diabetes were established. H&E was used to assess the histological changes of pancreas. IHC, FISH, western blot or qRT-PCR was employed to detect the expression of key molecules in primary islets or lipotoxic β-cells. Cell behaviors were detected by MTT, EdU incorporation assay, TUNEL assay and glucose-induced insulin secretion (GSIS). The associations among circMlxipl, Mbnl1 and Rbbp6 were validated by RIP and RNA pull-down assays, and the direct binding between Hdac3 and Mbnl1 promoter was examined by ChIP and luciferase assays. Co-IP was employed to assess the interaction between ChREBP and Rbbp6, as well as the ubiquitination of ChREBP.Hdac3 and ChREBP were upregulated, but Mbnl1 and circMlxipl were downregulated in islets from diabetic mice and lipotoxic β-cells. Mbnl1 overexpression protected against PA-induced impairments in lipotoxic β-cells through modulating back-splicing of circMlxipl and suppressing ChREBP. Hdac3 served as a transcriptional repressor of Mbnl1, and it was implicated in circMlxipl-mediated protection via regulating ChREBP expression in lipotoxic β-cells. Lack of circMlxipl inhibited Rbbp6-mediated ubiquitin-proteasomal degradation of ChREBP in lipotoxic β-cells. In vivo studies revealed that Hdac3 knockdown or Mbnl1 overexpression alleviated diabetes symptoms through circMlxipl-regulated ChREBP in diabetic mice.RESULTSHdac3 and ChREBP were upregulated, but Mbnl1 and circMlxipl were downregulated in islets from diabetic mice and lipotoxic β-cells. Mbnl1 overexpression protected against PA-induced impairments in lipotoxic β-cells through modulating back-splicing of circMlxipl and suppressing ChREBP. Hdac3 served as a transcriptional repressor of Mbnl1, and it was implicated in circMlxipl-mediated protection via regulating ChREBP expression in lipotoxic β-cells. Lack of circMlxipl inhibited Rbbp6-mediated ubiquitin-proteasomal degradation of ChREBP in lipotoxic β-cells. In vivo studies revealed that Hdac3 knockdown or Mbnl1 overexpression alleviated diabetes symptoms through circMlxipl-regulated ChREBP in diabetic mice.Mbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage.CONCLUSIONMbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage.
Abstract Background Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes. Methods Palmitic acid (PA)-treated β-cells, db/db mice and high fat diet (HFD)-fed mouse model of type 2 diabetes were established. H&E was used to assess the histological changes of pancreas. IHC, FISH, western blot or qRT-PCR was employed to detect the expression of key molecules in primary islets or lipotoxic β-cells. Cell behaviors were detected by MTT, EdU incorporation assay, TUNEL assay and glucose-induced insulin secretion (GSIS). The associations among circMlxipl, Mbnl1 and Rbbp6 were validated by RIP and RNA pull-down assays, and the direct binding between Hdac3 and Mbnl1 promoter was examined by ChIP and luciferase assays. Co-IP was employed to assess the interaction between ChREBP and Rbbp6, as well as the ubiquitination of ChREBP. Results Hdac3 and ChREBP were upregulated, but Mbnl1 and circMlxipl were downregulated in islets from diabetic mice and lipotoxic β-cells. Mbnl1 overexpression protected against PA-induced impairments in lipotoxic β-cells through modulating back-splicing of circMlxipl and suppressing ChREBP. Hdac3 served as a transcriptional repressor of Mbnl1, and it was implicated in circMlxipl-mediated protection via regulating ChREBP expression in lipotoxic β-cells. Lack of circMlxipl inhibited Rbbp6-mediated ubiquitin-proteasomal degradation of ChREBP in lipotoxic β-cells. In vivo studies revealed that Hdac3 knockdown or Mbnl1 overexpression alleviated diabetes symptoms through circMlxipl-regulated ChREBP in diabetic mice. Conclusion Mbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage.
Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes. Palmitic acid (PA)-treated β-cells, db/db mice and high fat diet (HFD)-fed mouse model of type 2 diabetes were established. H&E was used to assess the histological changes of pancreas. IHC, FISH, western blot or qRT-PCR was employed to detect the expression of key molecules in primary islets or lipotoxic β-cells. Cell behaviors were detected by MTT, EdU incorporation assay, TUNEL assay and glucose-induced insulin secretion (GSIS). The associations among circMlxipl, Mbnl1 and Rbbp6 were validated by RIP and RNA pull-down assays, and the direct binding between Hdac3 and Mbnl1 promoter was examined by ChIP and luciferase assays. Co-IP was employed to assess the interaction between ChREBP and Rbbp6, as well as the ubiquitination of ChREBP. Hdac3 and ChREBP were upregulated, but Mbnl1 and circMlxipl were downregulated in islets from diabetic mice and lipotoxic β-cells. Mbnl1 overexpression protected against PA-induced impairments in lipotoxic β-cells through modulating back-splicing of circMlxipl and suppressing ChREBP. Hdac3 served as a transcriptional repressor of Mbnl1, and it was implicated in circMlxipl-mediated protection via regulating ChREBP expression in lipotoxic β-cells. Lack of circMlxipl inhibited Rbbp6-mediated ubiquitin-proteasomal degradation of ChREBP in lipotoxic β-cells. In vivo studies revealed that Hdac3 knockdown or Mbnl1 overexpression alleviated diabetes symptoms through circMlxipl-regulated ChREBP in diabetic mice. Mbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage.
BackgroundDiabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes.MethodsPalmitic acid (PA)-treated β-cells, db/db mice and high fat diet (HFD)-fed mouse model of type 2 diabetes were established. H&E was used to assess the histological changes of pancreas. IHC, FISH, western blot or qRT-PCR was employed to detect the expression of key molecules in primary islets or lipotoxic β-cells. Cell behaviors were detected by MTT, EdU incorporation assay, TUNEL assay and glucose-induced insulin secretion (GSIS). The associations among circMlxipl, Mbnl1 and Rbbp6 were validated by RIP and RNA pull-down assays, and the direct binding between Hdac3 and Mbnl1 promoter was examined by ChIP and luciferase assays. Co-IP was employed to assess the interaction between ChREBP and Rbbp6, as well as the ubiquitination of ChREBP.ResultsHdac3 and ChREBP were upregulated, but Mbnl1 and circMlxipl were downregulated in islets from diabetic mice and lipotoxic β-cells. Mbnl1 overexpression protected against PA-induced impairments in lipotoxic β-cells through modulating back-splicing of circMlxipl and suppressing ChREBP. Hdac3 served as a transcriptional repressor of Mbnl1, and it was implicated in circMlxipl-mediated protection via regulating ChREBP expression in lipotoxic β-cells. Lack of circMlxipl inhibited Rbbp6-mediated ubiquitin-proteasomal degradation of ChREBP in lipotoxic β-cells. In vivo studies revealed that Hdac3 knockdown or Mbnl1 overexpression alleviated diabetes symptoms through circMlxipl-regulated ChREBP in diabetic mice.ConclusionMbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage.
ArticleNumber 229
Author Cao, Xiaopei
Jin, Jiewen
Wu, Liting
Xiao, Haipeng
Pei, Ling
Wei, Meilin
Xu, Changliu
Gong, Yingying
Li, Yanbing
Author_xml – sequence: 1
  givenname: Yingying
  surname: Gong
  fullname: Gong, Yingying
– sequence: 2
  givenname: Meilin
  surname: Wei
  fullname: Wei, Meilin
– sequence: 3
  givenname: Xiaopei
  surname: Cao
  fullname: Cao, Xiaopei
– sequence: 4
  givenname: Changliu
  surname: Xu
  fullname: Xu, Changliu
– sequence: 5
  givenname: Jiewen
  surname: Jin
  fullname: Jin, Jiewen
– sequence: 6
  givenname: Ling
  surname: Pei
  fullname: Pei, Ling
– sequence: 7
  givenname: Yanbing
  surname: Li
  fullname: Li, Yanbing
– sequence: 8
  givenname: Haipeng
  surname: Xiao
  fullname: Xiao, Haipeng
– sequence: 9
  givenname: Liting
  surname: Wu
  fullname: Wu, Liting
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39580381$$D View this record in MEDLINE/PubMed
BookMark eNpdkt1uFCEYhiemxv7oDXhgSDzxZBSGgYEjo5tWm7TRNHpM-JtdNiyMwGzaS_B2vJBek2y3Nq1HEHh48uXlPW4OQgy2aV4j-B4hRj9kBGEHW9j1LYSco5Y_a44Q6ViLKWEHj_aHzXHO60oj0pMXzSHmhEHM0FHz-1IFj9qNNU4Wa4D0xaYgi9takCfvtAtLEEegXdKX_tpNHiS7nH2FM7hSaqKtC9vot_XtYnV1-vk7KHMKcWsTKBG4sHLKFeDdFEu8rrpyUx-YWVf-9k-rrffAyI1c2pfN81H6bF_dryfNz7PTH4uv7cW3L-eLTxet7ntW2tFyoikakSID7Ikh0mispUQYY8oVHpAZu05yTUc2wA4TowkmWo0KKUuUwifN-d5rolyLKbmNTDciSifuDmJaCpmK094KYzCFmpJhkKyv2XFlNRqqExsyyl5W18e9a5pVjVDbUJL0T6RPb4JbiWXcCoQII5Dxanh3b0jx12xzERuXd6nIYOOcBUa4w5T2aIe-_Q9dxxp1zapSlHEGaQ8r9ebxSA-z_PvyCnR7QKeYc7LjA4Kg2PVK7Hslaq_EXa8Ex38B-EvC5Q
Cites_doi 10.2337/db15-0239
10.1038/s41467-022-32162-x
10.3390/cells10123328
10.1186/s43556-021-00043-2
10.1016/j.chembiol.2012.05.010
10.1155/2014/195739
10.2337/db11-0132
10.1016/j.imbio.2011.05.004
10.1007/s11892-024-01533-7
10.3390/ijms21176275
10.2217/epi.14.11
10.7150/thno.59546
10.1074/jbc.M109.095224
10.4239/wjd.v14.i3.130
10.1055/a-1624-2897
10.1038/nature10986
10.1002/wrna.1459
10.1016/j.molmet.2016.09.010
10.1016/j.imbio.2014.03.002
10.1101/gr.202895.115
10.1016/j.jcjd.2020.08.001
10.1038/s42255-022-00618-5
10.1073/pnas.0701916104
10.1007/s11356-021-12781-5
10.3389/fphys.2022.953880
10.7150/thno.42174
10.1016/S2213-8587(21)00113-3
10.1186/s12964-020-00681-z
10.1530/JME-20-0079
10.1038/srep31222
10.1016/j.jmb.2008.09.060
10.1155/2020/8708236
10.1186/s12575-021-00143-x
ContentType Journal Article
Copyright 2024. The Author(s).
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The Author(s) 2024 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
– notice: The Author(s) 2024 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s10020-024-00991-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1528-3658
EndPage 19
ExternalDocumentID oai_doaj_org_article_dd360c6577a842159bec172353d5fa4a
PMC11585089
39580381
10_1186_s10020_024_00991_9
Genre Journal Article
GeographicLocations United Kingdom--UK
United States--US
China
GeographicLocations_xml – name: United Kingdom--UK
– name: China
– name: United States--US
GrantInformation_xml – fundername: The Clinical Medical 5010 Project Foundation of Sun Yat-sen University
  grantid: 2017001
– fundername: National Natural Science Foundation of China
  grantid: 82200881
– fundername: National Natural Science Foundation of China
  grantid: 82200920
GroupedDBID ---
-ET
0R~
123
29M
2WC
36B
5RE
5VS
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFO
ACMJI
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IH2
IHR
ISR
ITC
KQ8
LGEZI
LOTEE
NADUK
NXXTH
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
RBZ
RNS
ROL
RPM
RSV
SDH
SJN
SOJ
SV3
TR2
UKHRP
WOQ
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c448t-fe95c61f1b57045d5adc3caa133369b371df22a9c6f870235dc535cbfb1be5bb3
IEDL.DBID DOA
ISSN 1528-3658
1076-1551
IngestDate Wed Aug 27 01:24:43 EDT 2025
Thu Aug 21 18:32:32 EDT 2025
Fri Jul 11 15:50:15 EDT 2025
Mon Jun 30 12:40:06 EDT 2025
Mon Jul 21 05:52:45 EDT 2025
Tue Jul 01 01:25:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Hdac3
Rbbp6
ChREBP
Lipotoxic β-cells
Mbnl1
circMlxipl
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c448t-fe95c61f1b57045d5adc3caa133369b371df22a9c6f870235dc535cbfb1be5bb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/dd360c6577a842159bec172353d5fa4a
PMID 39580381
PQID 3168980640
PQPubID 5066171
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_dd360c6577a842159bec172353d5fa4a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11585089
proquest_miscellaneous_3132366419
proquest_journals_3168980640
pubmed_primary_39580381
crossref_primary_10_1186_s10020_024_00991_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-11-23
PublicationDateYYYYMMDD 2024-11-23
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-11-23
  day: 23
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
– name: London
PublicationTitle Molecular medicine (Cambridge, Mass.)
PublicationTitleAlternate Mol Med
PublicationYear 2024
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References S Huang (991_CR10) 2021; 19
P Moela (991_CR19) 2014; 219
MA Herman (991_CR8) 2012; 484
MA Nauck (991_CR21) 2021; 9
G Yu (991_CR30) 2024; 24
XO Zhang (991_CR32) 2016; 26
L Li (991_CR16) 2007; 104
P Zhang (991_CR31) 2015; 64
S Sen (991_CR26) 2010; 285
Q Yang (991_CR29) 2021; 2
PV Dludla (991_CR5) 2023; 14
LR Motadi (991_CR20) 2011; 216
A Huang (991_CR9) 2020; 10
U Galicia-Garcia (991_CR6) 2020; 21
M Chibi (991_CR1) 2008; 384
L Wu (991_CR28) 2020; 65
G Jing (991_CR14) 2016; 5
EA Vilas-Boas (991_CR27) 2021; 10
KL Corbin (991_CR3) 2021; 23
X Jiang (991_CR12) 2020; 2020
LS Katz (991_CR15) 2022; 13
V Plaisance (991_CR23) 2014; 2014
E Schleicher (991_CR25) 2022; 130
A Gupta (991_CR7) 2021; 28
BC Meier (991_CR18) 2014; 6
CA Nutter (991_CR22) 2018; 9
DH Chou (991_CR2) 2012; 19
Diabetes Canada Clinical Practice Guidelines Expert C (991_CR4) 2020; 44
CA Robson-Doucette (991_CR24) 2011; 60
C Jiaxin (991_CR13) 2021; 11
C Jain (991_CR11) 2022; 4
S Zhang (991_CR33) 2022; 13
P Malakar (991_CR17) 2016; 6
References_xml – volume: 64
  start-page: 4158
  year: 2015
  ident: 991_CR31
  publication-title: Diabetes
  doi: 10.2337/db15-0239
– volume: 13
  start-page: 4423
  year: 2022
  ident: 991_CR15
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-32162-x
– volume: 10
  start-page: 3328
  year: 2021
  ident: 991_CR27
  publication-title: Cells
  doi: 10.3390/cells10123328
– volume: 2
  start-page: 23
  year: 2021
  ident: 991_CR29
  publication-title: Mol Biomed
  doi: 10.1186/s43556-021-00043-2
– volume: 19
  start-page: 669
  year: 2012
  ident: 991_CR2
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2012.05.010
– volume: 2014
  start-page: 195739
  year: 2014
  ident: 991_CR23
  publication-title: J Diabetes Res
  doi: 10.1155/2014/195739
– volume: 60
  start-page: 2710
  year: 2011
  ident: 991_CR24
  publication-title: Diabetes
  doi: 10.2337/db11-0132
– volume: 216
  start-page: 1065
  year: 2011
  ident: 991_CR20
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2011.05.004
– volume: 24
  start-page: 27
  year: 2024
  ident: 991_CR30
  publication-title: Curr Diab Rep
  doi: 10.1007/s11892-024-01533-7
– volume: 21
  start-page: 6275
  year: 2020
  ident: 991_CR6
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21176275
– volume: 6
  start-page: 209
  year: 2014
  ident: 991_CR18
  publication-title: Epigenomics
  doi: 10.2217/epi.14.11
– volume: 11
  start-page: 7507
  year: 2021
  ident: 991_CR13
  publication-title: Theranostics
  doi: 10.7150/thno.59546
– volume: 285
  start-page: 25426
  year: 2010
  ident: 991_CR26
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.095224
– volume: 14
  start-page: 130
  year: 2023
  ident: 991_CR5
  publication-title: World J Diabetes
  doi: 10.4239/wjd.v14.i3.130
– volume: 130
  start-page: S1
  year: 2022
  ident: 991_CR25
  publication-title: Exp Clin Endocrinol Diabetes
  doi: 10.1055/a-1624-2897
– volume: 484
  start-page: 333
  year: 2012
  ident: 991_CR8
  publication-title: Nature
  doi: 10.1038/nature10986
– volume: 9
  start-page: 29280295
  year: 2018
  ident: 991_CR22
  publication-title: Wiley Interdiscip Rev RNA
  doi: 10.1002/wrna.1459
– volume: 5
  start-page: 1208
  year: 2016
  ident: 991_CR14
  publication-title: Mol Metab
  doi: 10.1016/j.molmet.2016.09.010
– volume: 219
  start-page: 593
  year: 2014
  ident: 991_CR19
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2014.03.002
– volume: 26
  start-page: 1277
  year: 2016
  ident: 991_CR32
  publication-title: Genome Res
  doi: 10.1101/gr.202895.115
– volume: 44
  start-page: 575
  year: 2020
  ident: 991_CR4
  publication-title: Can J Diabetes
  doi: 10.1016/j.jcjd.2020.08.001
– volume: 4
  start-page: 1097
  year: 2022
  ident: 991_CR11
  publication-title: Nat Metab
  doi: 10.1038/s42255-022-00618-5
– volume: 104
  start-page: 7951
  year: 2007
  ident: 991_CR16
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0701916104
– volume: 28
  start-page: 19601
  year: 2021
  ident: 991_CR7
  publication-title: Environ Sci Pollut Res Int
  doi: 10.1007/s11356-021-12781-5
– volume: 13
  start-page: 953880
  year: 2022
  ident: 991_CR33
  publication-title: Front Physiol
  doi: 10.3389/fphys.2022.953880
– volume: 10
  start-page: 3503
  year: 2020
  ident: 991_CR9
  publication-title: Theranostics
  doi: 10.7150/thno.42174
– volume: 9
  start-page: 525
  year: 2021
  ident: 991_CR21
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(21)00113-3
– volume: 19
  start-page: 35
  year: 2021
  ident: 991_CR10
  publication-title: Cell Commun Signal
  doi: 10.1186/s12964-020-00681-z
– volume: 65
  start-page: 149
  year: 2020
  ident: 991_CR28
  publication-title: J Mol Endocrinol
  doi: 10.1530/JME-20-0079
– volume: 6
  start-page: 31222
  year: 2016
  ident: 991_CR17
  publication-title: Sci Rep
  doi: 10.1038/srep31222
– volume: 384
  start-page: 908
  year: 2008
  ident: 991_CR1
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2008.09.060
– volume: 2020
  start-page: 8708236
  year: 2020
  ident: 991_CR12
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2020/8708236
– volume: 23
  start-page: 7
  year: 2021
  ident: 991_CR3
  publication-title: Biol Proced Online
  doi: 10.1186/s12575-021-00143-x
SSID ssj0021545
Score 2.4296665
Snippet Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of diabetes....
BackgroundDiabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of...
Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of pathophysiology of...
Abstract Background Diabetes, a global epidemic, is the leading cause of mortality globally. The aim of this study is to get better understanding of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 229
SubjectTerms Alternative Splicing
Animals
Apoptosis
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism
ChREBP
circMlxipl
Cloning
Diabetes
Diabetes Mellitus, Type 2 - genetics
Diabetes Mellitus, Type 2 - metabolism
Diet, High-Fat - adverse effects
Disease Models, Animal
DNA-Binding Proteins
Gene Expression Regulation
Glucose
Hdac3
Histone Deacetylases - genetics
Histone Deacetylases - metabolism
Insulin
Insulin-Secreting Cells - metabolism
Lipotoxic β-cells
Male
Mbnl1
Mice
Palmitic Acid
Rbbp6
RNA, Circular - genetics
RNA, Circular - metabolism
RNA-Binding Proteins - genetics
RNA-Binding Proteins - metabolism
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagCIkL4p-UgozEDVms49ixT4hWrSqkRaii0t4i_8RspCVZdtOqfQRehwfhmZhxslsWIS45JHZkeT57vvGMZwh5MwkeDJ84YaXleCWnzpkV2rIoaqVjXnqdkiRNP6nT8-LjTM7GA7f1GFa52RPTRh06j2fk77DAktHod3q__M6wahR6V8cSGrfJHUxdhqguZzcGF9KDIeZQMaQGm0szWuHVOTScQEMxJEmcmR3FlPL3_4t0_h07-YcyOnlA7o8skn4YxP6Q3KrbR-TuUFfy-jH5MXXtgrN0KwQYJU0u8Tal-KZrdFiDvqJdpL5Z-eniqlku6GqoSV-v6ZlzS8WaFvatS-h7ND87PvxMQTO1GO1J-4427bxxTU8XzbLruyv4XX8NHQKgJNBfPxk6A2iw32CrekLOT46_HJ2yseYC82Co9SzWRnrFI3eyBLYXpAVhemvBlBXKOFHyEPPcGq8irPRcyOClkN5Fx10tnRNPyV7btfVzQrUqjNBO1PAsIiBFR68mxmGcitGaZ-TtZsKr5ZBao0omiVbVIJ4KxFMl8VQmI4cok21LTIudXnSrr9W4yqoQhJp4JcvS6gLEbwChwNCEFEFGW9iMHGwkWo1rdV3dICsjr7efYZXhbNm27i6wjciFUgWHcTwbALAdiTBSo781I3oHGjtD3f3SNvOUyRvouAaGbPb_P64X5F6OSOWc5eKA7PWri_olcKHevUqA_w2Zbgoj
  priority: 102
  providerName: ProQuest
Title Mbnl1-mediated alternative splicing of circMlxipl regulates Rbbp6-involved ChREBP turnover to inhibit lipotoxicity-induced β-cell damage
URI https://www.ncbi.nlm.nih.gov/pubmed/39580381
https://www.proquest.com/docview/3168980640
https://www.proquest.com/docview/3132366419
https://pubmed.ncbi.nlm.nih.gov/PMC11585089
https://doaj.org/article/dd360c6577a842159bec172353d5fa4a
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NitswEBbtlkIvpf91uw0q9FZEI8uSpWOzZFkKWZbQhdCL0Y9FDFk5JN6y-wh9nT5In6kj2QmbUuilFx1syR5rZjTfWKMZhD6MnQXHx49JqWk8klPnRDOpiWe1kD4vrUxJkmbn4uyy-LLgizulvmJMWJ8euJ-4T84xMbaCl6WWBdgnBS8Fo8s4c9zrIkEjsHk7Z2pwtSIw2B2RkSIelItuEtgjEiERJerADKVs_X-DmH9GSt4xPadP0OMBM-LPPa1P0b06PEMP-yqSt8_Rj5kJK0rSGRDAjzhtgIeU0Btv4_Y0WCfcemybjZ2tbpr1Cm_6CvT1Fs-NWQvSBFilvsPYk-V8OrnAYIdCjO3EXYubsGxM0-FVs2679gYe193CAAcy4fCvnyT--sdOX8HC9AJdnk6_npyRocICseCWdcTXiltBPTW8BGznuAbWWa3BcWVCGVZS5_NcKys86DVMurOccWu8oabmxrCX6Ci0oX6NsBSFYtKwGtrCg1xIb8VYmRiVoqSkGfq4m_Bq3SfSqJIDIkXVs6cC9lSJPZXK0CTyZN8zJsFOF0A0qkE0qn-JRoaOdxytBs3cVrFQl5Jx_zJD7_e3QafibOlQt9exD8uZEAUFOl71ArCnhCku4-5qhuSBaByQengnNMuUtxvAtwQ8rN78j497ix7lUZ4pJTk7Rkfd5rp-B_ioMyN0v1yUI_RgMj2_mI-SYkA7n3z7DVpuFAU
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKEYIL4p-FAkaCE7LYxLFjHxCipdWWditUtVJvwXbsbqQlWXZT6D4CL8OBB-GZmEk2WxYhbr3kkD9Zmc8z32T-CHnRzx04PqHPUhNhSY6PmeHKsMC9VCFOnWqaJA0P5OA4-XAiTtbIj64WBtMqO53YKOq8cviP_DUOWNIK405vJ18YTo3C6Go3QqOFxZ6ffwOXbfZm9z3I92Uc72wfbQ3YYqoAc-CK1Cx4LZyMQmRFCnwmFwaW64wBZ41LbXka5SGOjXYyAJZjLnInuHA22Mh6YS2H914hV8Hw9tHZS08uHDykI22Oo2RIRboiHSWxVA8dNbCIDElZxPSKIWzmBfyL5P6dq_mH8du5RW4uWCt918LsNlnz5R1yrZ1jOb9Lvg9tOY5YU4UCDJY2IfiyaSlOZxggB_tIq0BdMXXD8XkxGdOpP8XBYX5GD62dSFaUoCe_wrNbo8PtzY8ULGGJ2aW0rmhRjgpb1HRcTKq6OofX1XN4IAdU5vTXT4bBB5qbz6Aa75HjS5HGfbJeVqV_SKiSiebKcg_HJAAyVXCyry3mxWiloh551X3wbNK28sgaF0jJrBVPBuLJGvFkukc2USbLO7ENd3Oimp5mi12d5TmXfSdFmhqVgPg17AhghFzwXASTmB7Z6CSaLXTDLLtAco88X16GXY1fy5S-OsN7eMylTCJYx4MWAMuVcC0Uxnd7RK1AY2Wpq1fKYtR0Dgf6r4CR60f_X9czcn1wNNzP9ncP9h6TGzGiNopYzDfIej0980-Ah9X2aQN-Sj5d9m77De92SCQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJxAviOsoDDASPCFrTRw79gNCdGu1MVpVE5P2FmzHXiOVpLQZrD-Bv8MjP4LfxHEuhSLE217ykJuOcr5zy7kh9KKXGgh8XI_EKvAtOTYkigpFHLVcuDA2ohqSNBrzw9Po3Rk720I_2l4YX1bZ6sRKUaeF8f_I9_yCJSl83mnPNWURk4Phm_ln4jdI-Uxru06jhsixXX2F8G35-ugAeP0yDIeDD_uHpNkwQAyEJSVxVjLDAxdoFoNvkzIFpBulIHCjXGoaB6kLQyUNd4DrkLLUMMqMdjrQlmlN4b3X0Hbso6IO2u4PxpOTdbjnnZO64pET75i0LTuC-8Y9H7aBfSTeRQuI3DCL1faAf7m8f1du_mEKh7fRrcaHxW9r0N1BWza_i67XWy1X99C3kc5nAal6UsCfxVVCPq8GjOOlT5eDtcSFwyZbmNHsMpvP8MKe-zVidolPtJ5zkuWgNb_As_vTk0F_gsEu5r7WFJcFzvJpprMSz7J5URaX8LpyBQ-kgNEU__xOfCoCp-oTKMr76PRK-PEAdfIitw8RFjySVGhq4Rg5wKlwhvek9lUyUoigi161HzyZ14M9kiogEjyp2ZMAe5KKPYnsor7nyfpOP5S7OlEszpNGxpM0pbxnOItjJSJgvwT5AP-QMpoypyLVRbstR5NGUyyT37juoufryyDj_mup3BYX_h4aUs6jAOjYqQGwpoRKJny2t4vEBjQ2SN28kmfTao44BAMC_HP56P90PUM3QNKS90fj48foZuhBGwQkpLuoUy4u7BNwykr9tEE_Rh-vWuB-AZqhTb8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mbnl1-mediated+alternative+splicing+of+circMlxipl+regulates+Rbbp6-involved+ChREBP+turnover+to+inhibit+lipotoxicity-induced+%CE%B2-cell+damage&rft.jtitle=Molecular+medicine+%28Cambridge%2C+Mass.%29&rft.au=Gong%2C+Yingying&rft.au=Wei%2C+Meilin&rft.au=Cao%2C+Xiaopei&rft.au=Xu%2C+Changliu&rft.date=2024-11-23&rft.issn=1528-3658&rft.eissn=1528-3658&rft.volume=30&rft.issue=1&rft_id=info:doi/10.1186%2Fs10020-024-00991-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s10020_024_00991_9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-3658&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-3658&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-3658&client=summon